Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orthocell Ltd ( (AU:OCC) ) has provided an announcement.
Orthocell Ltd has announced the appointment of Mr. Michael McNulty as a director, effective from September 1, 2025. Mr. McNulty holds 2,000,000 unlisted options and 56,169 ordinary fully paid shares through McNulty Family Pty Ltd and his spouse, indicating a significant personal investment in the company. This appointment may enhance Orthocell’s strategic direction and strengthen its position in the regenerative medicine sector.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd operates in the biotechnology industry, focusing on regenerative medicine. The company specializes in developing and commercializing products for the repair and regeneration of soft tissue injuries, with a market focus on advancing innovative medical solutions.
Average Trading Volume: 619,748
Technical Sentiment Signal: Buy
Current Market Cap: A$292.5M
For detailed information about OCC stock, go to TipRanks’ Stock Analysis page.